Product Reports Resources Pricing Login Book a demo

Accolade

Health Tech & Medtech · Plymouth Township, United States · Founded 2007 · IPO 2020

A personalized health and benefits solution that dramatically improves the experience, outcomes and cost of healthcare for employers, health plans and their members

Valuation $576M
Revenue $414M

Talent graph

Accolade's talent

Book a demo to see the people
Employees mapped 1,320 incl. 9 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 6 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on Accolade's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage
Humana
Accretive
Series B+ 5 investors entered at this stage

Global footprint

Where Accolade has talent and traffic

Workforce by country
19 countries with
team presence
🇺🇸 United States78.1%
🇨🇿 Czech Republic18.8%
🇨🇦 Canada1.6%
🇮🇹 Italy0.2%
🇧🇷 Brazil0.1%
Top 5 of 19 shown
Web traffic by country
130K monthly visits
across markets
🇺🇸 United States93.8%
🇬🇧 United Kingdom1.5%
🇨🇦 Canada1.4%
🇮🇳 India1.2%
🇸🇬 Singapore0.8%
Top 5 markets shown

Patent intelligence

$2M patent portfolio · 6 active families

Estimated portfolio value
$2M
0.30% of market cap · 77.9× smaller than top peer Fitbit ($133M)
6 active patent families
Where Accolade innovates Communications systemElectronic equipmentEncoderForward error correctionMedical treatment

Where Accolade concentrates vs peers

Each axis is a top-10 topic across Accolade and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Accolade's 3 investments and acquisitions.

Every disclosed deal where Accolade appeared as a backer or acquirer, 2019–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Accolade's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Accolade deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Accolade's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Accolade

        An AI-synthesized read of the highest-engagement posts about Accolade on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Accolade on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.